Evidence map›Paper›PMID 41416335›Full record

ArticleCureus2025

Polyarteritis Nodosa With Mesenteric, Hepatic, and Musculoskeletal Manifestations in a 36-Year-Old Nigerian Male Patient: A Case Report.

Oluyemisi Okwudishu, Olasunkanmi Olatunbosun, Chika S Chijioke, Victor C Okebalama, Bonaventure Ogbodo, Olutomiwa Omokore, Joshua Odeyinka, Jennifer O Ibhiedu, Onyebuchukwu Eke, Obioma Aririsukwu

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Oluyemisi OkwudishuDepartment of Internal Medicine, Babcock University Teaching Hospital, Ilishan-Remo, NGA.
Olasunkanmi OlatunbosunDepartment of Acute Medicine, Wye Valley NHS, Hereford, GBR.
Chika S ChijiokeDepartment of Haematology, University Hospital of Wales, Cardiff, GBR.
Victor C OkebalamaDepartment of Anatomic Pathology and Forensic Medicine, Babcock University Teaching Hospital, Ilishan-Remo, NGA.
Bonaventure OgbodoDepartment of Morbid Anatomy, University of Nigeria Teaching Hospital, Enugu, NGA.
Olutomiwa OmokoreDepartment of Internal Medicine, Babcock University Teaching Hospital, Ilishan-Remo, NGA.
Joshua OdeyinkaDepartment of Surgery, Babcock University Teaching Hospital, Ilishan-Remo, NGA.
Jennifer O IbhieduDepartment of Internal Medicine, Babcock University Teaching Hospital, Ilishan-Remo, NGA.
Onyebuchukwu EkeDepartment of Pharmacology and Therapeutics, Ebonyi State University, Abakaliki, NGA.
Obioma AririsukwuDepartment of Medicine, St Francois Medical Centre, Abuja, NGA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polyarteritis nodosa (PAN) is a rare systemic necrotizing vasculitis affecting medium and small arteries, with heterogeneous clinical manifestations ranging from constitutional symptoms to life-threatening organ ischemia. We present the case of a 36-year-old male patient with PAN manifesting as severe abdominal pain and bilateral upper limb ischemia, highlighting the diagnostic and therapeutic challenges of this condition. Initial evaluation revealed elevated inflammatory markers and characteristic arterial stenosis with aneurysmal dilation on Doppler ultrasound, supporting a PAN diagnosis with negative antineutrophil cytoplasmic antibody (ANCA) serology. Treatment with high-dose glucocorticoids induced remission, underscoring the efficacy of immunosuppression in managing this disease. This case illustrates the importance of considering PAN in patients with unexplained ischemic symptoms, particularly in the absence of ANCA positivity. While glucocorticoids remain first-line therapy, emerging evidence supports the use of biologic agents in refractory cases. The discussion explores the evolving treatment paradigms, including the role of cyclophosphamide, tumor necrosis factor (TNF) inhibitors, and rituximab, while emphasizing the need for risk-stratified management. Given PAN's variable presentation and potential for severe complications, early recognition and tailored immunosuppressive therapy are crucial for optimizing outcomes.

Indexed as

anca-negative vasculitisimmunosuppressive therapyischemic complicationsnigerian malepolyarteritis nodosasystemic vasculitis

Identifiers

PMID41416335
PMCPMC12709664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.